In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forging a Path for Pharmacogenomics at the FDA

Executive Summary

The FDA is now sorting through public comments on draft guidance the agency issued recently, to encourage drug developers to voluntarily share pharmacogenomic data with it. Companies have some serious concerns that the agency means to address by the summer with the issuance of formal guidelines and the launching of a public forum for discussion about pharmacogenomics.
Advertisement

Related Content

Pharmacogenomics: Promises and Problems
A Little Knowledge: The FDA's Public Approach to Safety
The Outlook for Pharmacogenomics Testing in Primary Care
The Outlook for Pharmacogenomics Testing in Primary Care
AstraZeneca's Iressa Problem
Waiting for New Words on Pharmacogenomics
Waiting for New Words on Pharmacogenomics
Nanogen Stakes A Shape-Shifting Market
Glaxo Puts SNPs to Work

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel